Canine flu therapeutics sales will grow through 2036, led by vaccines at 42.0% of the treatment type segment in 2026, driven by companion animal healthcare demand and preventive vaccination programs. The market is projected to reach USD 2.3 billion in 2026 and USD 3.30 billion by 2036, creating an incremental opportunity of USD 1.05 billion.